BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 StudySusan Bal, Jesús G. Berdeja, Wei-Ming Kao et al.|Blood|2023Cited by 56
Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)Susan Bal, Myo Htut, Larry D. Anderson et al.|Blood|2024Cited by 23
BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy ResultsSusan Bal, Omar Nadeem, Myo Htut et al.|Blood|2024Cited by 6
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myelomaSusan Bal, Jesús G. Berdeja, Myo Htut et al.|Blood|2026Cited by 1
Assessment of normal plasma cell biomarkers after arlocabtagene autoleucel (arlo-cel) treatment in patients with ≥3L relapsed refractory multiple myeloma (MM).Kristina M. Jordahl, Safiyyah Ziyad, Wei-Ming Kao et al.|Journal of Clinical Oncology|2025Cited by 1